# Chaga Mushroom (Inonotus obliquus var. obliquus)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/chaga-mushroom-inonotus-obliquus-var-obliquus
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 1 / 10
**Category:** Mushroom/Fungi
**Also Known As:** Chaga, Birch Conk, Cinder Conk, Black Mass, Befungin (Russian pharmaceutical preparation), Chaga Mushroom (Inonotus obliquus (Ach. ex Pers.) Pilát), Clinker Polypore, Chaga Mushroom, Inonotus obliquus var. obliquus

## Overview

Inonotus obliquus var. obliquus contains lanosterol, ergosterol peroxide, betulinic acid, inotodiol, and polyphenols that collectively modulate [antioxidant](/ingredients/condition/antioxidant) enzyme systems, cholesterol biosynthesis, and immune-[inflammatory](/ingredients/condition/inflammation) signaling pathways. Preclinical data demonstrate cytotoxic activity of betulin nanosuspensions against MDA-MB-231 breast cancer cells at an IC50 of 38 µg/mL, and total polyphenol content reaching 287 mg gallic acid equivalents per gram dry weight in Alnus-derived conks, underscoring potent in vitro antioxidant capacity.

## Health Benefits

- **[Antioxidant Activity](/ingredients/condition/antioxidant)**: Polyphenols and triterpenoids in chaga scavenge free radicals, quantified via DPPH assay at concentrations equivalent to 287 mg gallic acid equivalents per gram dry weight in Alnus-grown conks; ergosterol peroxide contributes additional radical-quenching activity through its sterol peroxide structure.
- **[Immunomodulat](/ingredients/condition/immune-support)ion**: Beta-glucan polysaccharides and terpenoids activate macrophage and natural killer cell responses, stimulating cytokine production and enhancing innate immune surveillance; this activity is documented across multiple preclinical in vitro and rodent models.
- **Antitumor Potential**: Betulinic acid (up to 635 µg/g in Alnus conks), inotodiol (up to 8961 µg/g), and lanosterol (up to 1023 µg/g) exhibit cytostatic and cytotoxic effects against multiple cancer cell lines, with betulin nanosuspensions demonstrating improved cytotoxicity (IC50 38 µg/mL) over betulinic acid alone due to enhanced solubilization.
- **[Hepatoprotective](/ingredients/condition/detox) Effects**: Polyphenolic compounds and triterpenoids reduce oxidative stress markers in hepatocyte models, supporting liver cell integrity; preclinical animal studies suggest attenuation of hepatotoxin-induced liver damage through antioxidant and anti-inflammatory co-mechanisms.
- **Anti-Inflammatory Properties**: Phenolic acids including protocatechuic acid (8.6–87.6 µg/g), caffeic acid, and p-coumaric acid suppress [pro-inflammatory cytokine](/ingredients/condition/inflammation) expression and inhibit NF-κB signaling pathways in cell-based models, reducing markers of acute and chronic inflammation.
- **Antiviral Activity**: In vitro and limited in vivo studies indicate that chaga extracts may inhibit viral replication, including preliminary evidence for SARS-CoV-2 inhibition; the antiviral mechanism is attributed to polyphenolic interference with viral entry and replication machinery, though human data remain absent.
- **Hypoglycemic and Metabolic Regulation**: Chaga polysaccharides and triterpenoids modulate glucose uptake and [insulin sensitivity](/ingredients/condition/weight-management) in rodent diabetic models, and lanosterol's role in cholesterol biosynthesis inhibition suggests additional lipid-regulating potential relevant to metabolic syndrome.

## Mechanism of Action

Lanosterol and ergosterol peroxide modulate the mevalonate pathway by inhibiting key enzymes in cholesterol biosynthesis while simultaneously acting as direct antioxidants through their hydroxyl and peroxide functional groups, reducing [lipid peroxidation](/ingredients/condition/antioxidant) markers in cell membranes. Betulinic acid selectively induces apoptosis in tumor cells by disrupting [mitochondrial](/ingredients/condition/energy) membrane potential, activating caspase-3 and caspase-9 cascades, and suppressing Bcl-2 anti-apoptotic protein expression, while inotodiol exerts cytostatic effects through cell cycle arrest at the G1/S checkpoint. Polyphenols including protocatechuic acid and caffeic acid inhibit [NF-κB](/ingredients/condition/inflammation) nuclear translocation, downregulate COX-2 and iNOS gene expression, and chelate transition metal ions to prevent Fenton reaction-driven oxidative damage. [Beta-glucan](/ingredients/condition/immune-support) polysaccharides bind pattern recognition receptors—particularly Dectin-1 on macrophages and dendritic cells—triggering downstream MAPK and NF-κB-mediated upregulation of IL-6, TNF-α, and interferon-gamma, thereby priming both innate and adaptive immune responses.

## Clinical Summary

No human randomized controlled trials have been published that establish clinical efficacy, optimal dosing, or validated health outcomes for Inonotus obliquus var. obliquus supplementation in any disease indication. Preclinical evidence across 171 reviewed studies documents measurable antitumor, [antioxidant](/ingredients/condition/antioxidant), [immunomodulatory](/ingredients/condition/immune-support), and antiviral activities in cell lines and animal models, with quantified endpoints such as IC50 values and DPPH inhibition percentages. The absence of phase I or phase II human trials means that effect sizes, therapeutic windows, and population-level response rates remain entirely unknown. Confidence in clinical benefit is therefore low, and existing data should be interpreted as hypothesis-generating rather than practice-informing.

## Nutritional Profile

Inonotus obliquus var. obliquus conks contain a complex matrix of bioactive constituents rather than conventional macronutrients in significant dietary quantities. Triterpenoids are present at highly variable concentrations depending on host tree: betulin (111–159 µg/g DW), betulinic acid (20–635 µg/g DW), inotodiol (up to 8961 µg/g DW), and lanosterol (up to 1023 µg/g DW). Total polyphenols reach up to 287 mg gallic acid equivalents per gram DW, with total flavonols at approximately 336 µg quercetin equivalents per gram DW; individual phenolic acids include protocatechuic acid (8.6–87.6 µg/g), caffeic acid, p-coumaric acid, and p-hydroxybenzoic acid. Indole compounds such as L-tryptophan (4.0–30.4 µg/g in mycelial culture), tryptamine, and melatonin are present at low but measurable concentrations. Mineral bioelements include potassium, sodium, calcium, magnesium, zinc, manganese, iron, and copper; ergosterol and ergosterol peroxide are present as key sterols. Betulin's low aqueous solubility is a critical bioavailability limitation, while polyphenols and water-soluble polysaccharides are more readily extracted and absorbed.

## Dosage & Preparation

- **Hot Water Extract (Decoction)**: Traditional Russian and Siberian preparation involves simmering dried chaga conk chunks at 50–60°C for several hours; no clinically validated dose established, but traditional use ranged from 1–3 cups of tea daily.
- **Ethanolic Extract**: Laboratory and commercial preparations use ethanol (70–96%) to isolate triterpenoids including betulinic acid, inotodiol, and lanosterol; standardized extracts may list triterpenoid content but no regulatory standard exists.
- **Dried Powder**: Whole conk ground to powder and encapsulated; commercial products typically range from 500–1500 mg per capsule, taken 1–3 times daily, though dose is empirical and not clinically validated.
- **Dual Extraction (Water + Alcohol)**: Increasingly common commercial method combining hot water polysaccharide extraction with ethanol triterpenoid extraction to capture the full phytochemical spectrum; considered the most comprehensive form.
- **Standardization**: No internationally recognized standardization benchmark exists; some products are standardized to polyphenol content (e.g., ≥2% by GAE) or [beta-glucan](/ingredients/condition/immune-support) percentage, but these metrics are manufacturer-defined.
- **Bioavailability Note**: Betulin has poor aqueous solubility that significantly limits oral bioavailability; nanosuspension technology has been explored preclinically to improve cytotoxic potency, but such formulations are not yet commercially standardized.

## Safety & Drug Interactions

Preclinical data indicate low acute toxicity for individual compounds such as betulin and betulinic acid at tested concentrations, and [hepatoprotective](/ingredients/condition/detox) activity in animal models suggests an absence of gross hepatotoxicity at moderate doses; however, no formal human toxicological studies, maximum tolerated dose studies, or long-term safety trials have been conducted. Chaga contains high concentrations of oxalates, and case reports have documented oxalate nephropathy in individuals consuming large quantities of chaga tea over extended periods, representing a clinically important contraindication for individuals with kidney disease or a history of calcium oxalate urolithiasis. Theoretical drug interactions exist with anticoagulants (e.g., warfarin) due to chaga's reported platelet aggregation inhibition, and with antidiabetic medications given preclinical hypoglycemic activity, warranting caution in patients on these drug classes. Pregnancy and lactation safety has not been evaluated in any clinical context, and use during these periods is not recommended; individuals with autoimmune conditions should exercise caution given the immunostimulatory polysaccharide content.

## Scientific Research

The body of evidence for Inonotus obliquus var. obliquus is derived predominantly from in vitro cell culture experiments and in vivo rodent studies, with a systematic review encompassing 171 published articles confirming the absence of human randomized controlled trials reporting specific sample sizes or effect sizes. Quantified preclinical outcomes include IC50 values for cytotoxicity (e.g., 38 µg/mL for betulin nanosuspensions against MDA-MB-231 cells), DPPH radical scavenging expressed as mg gallic acid equivalents per gram, and mycelial biomass yields (2.8–11.2 g/L dry mass) in controlled culture conditions. [Antiviral](/ingredients/condition/immune-support) activity against SARS-CoV-2 has been explored in silico and in limited in vitro/in vivo models, but no peer-reviewed human clinical trial has validated these findings. The current evidence base is preclinical in nature, and while mechanistic plausibility is well-supported across multiple compound classes, clinical translation to standardized human supplementation regimens has not yet occurred.

## Historical & Cultural Context

Chaga has been used for centuries in Russian folk medicine, Siberian shamanic traditions, and across Northern European cultures, where it was consumed as a tea brewed from birch-harvested conks and credited with [anti-aging](/ingredients/condition/longevity), anticancer, and gastrointestinal protective properties. In 16th-century Russia, Tsar Ivan the Terrible was reportedly treated with chaga preparations for lip cancer, and the mushroom was formally documented in Russian botanical and medical literature by the 18th century. In China and Korea, related Inonotus species were integrated into traditional pharmacopeias under the broader category of medicinal bracket fungi used for longevity and [immune support](/ingredients/condition/immune-support). Alexander Solzhenitsyn's 1966 novel 'Cancer Ward' brought renewed international attention to chaga as a folk cancer remedy used by Siberian peasants, spurring mid-20th century Soviet pharmaceutical investigations into its bioactive constituents.

## Synergistic Combinations

Chaga's triterpenoids, particularly betulinic acid, may synergize with other [mitochondrial](/ingredients/condition/energy) apoptosis-inducing agents such as quercetin (found in many botanical extracts) by co-targeting Bcl-2 family proteins and amplifying caspase activation in tumor cell models. Combination with vitamin C has been proposed to enhance polyphenol stability and extend the [antioxidant](/ingredients/condition/antioxidant) half-life of phenolic acids in aqueous preparations, as ascorbate recycling regenerates oxidized polyphenol intermediates. In traditional Siberian practice, chaga tea was frequently consumed alongside [adaptogenic herb](/ingredients/condition/stress)s such as Eleutherococcus senticosus (Siberian ginseng), a pairing that may provide complementary [immunomodulatory](/ingredients/condition/immune-support) and stress-axis regulatory activity through distinct receptor-level mechanisms including Dectin-1 and glucocorticoid receptor pathways respectively.

## Frequently Asked Questions

### What are the main bioactive compounds in chaga mushroom?

Chaga mushroom contains over 200 identified compounds, with the most pharmacologically significant being triterpenoids (betulin at 111–159 µg/g DW, betulinic acid up to 635 µg/g DW, inotodiol up to 8961 µg/g DW, and lanosterol up to 1023 µg/g DW), polyphenols (up to 287 mg gallic acid equivalents per gram DW), ergosterol peroxide, beta-glucan polysaccharides, and phenolic acids including protocatechuic and caffeic acid. Concentrations vary significantly depending on host tree species, geographic origin, and extraction method, with Alnus incana-derived conks generally yielding higher triterpenoid levels than Betula pendula specimens.

### Is there clinical trial evidence supporting chaga mushroom health claims?

Currently, no human randomized controlled trials have been published to validate any specific health claim for Inonotus obliquus var. obliquus, and a systematic review of 171 studies confirmed that all documented evidence is derived from in vitro cell culture experiments and in vivo animal models. Quantified preclinical outcomes include an IC50 of 38 µg/mL for betulin nanosuspensions against MDA-MB-231 breast cancer cells and robust DPPH radical scavenging activity, but these findings cannot be directly extrapolated to human therapeutic effects without controlled clinical investigation.

### What are the side effects and safety concerns of taking chaga mushroom?

Chaga mushroom has a low acute toxicity profile based on preclinical data, but its high oxalate content poses a genuine risk of oxalate nephropathy—kidney damage from calcium oxalate crystal deposition—particularly in individuals consuming large quantities over extended periods, as documented in published case reports. Patients taking anticoagulants such as warfarin or antidiabetic medications should exercise caution due to chaga's theoretical platelet-inhibiting and blood glucose-lowering activities, and use during pregnancy or lactation is not recommended due to a complete absence of safety data in these populations.

### How should chaga mushroom be prepared to maximize its bioactive content?

Dual extraction—combining a hot water extraction (50–60°C) to capture water-soluble beta-glucan polysaccharides and phenolic acids with a separate 70–96% ethanol extraction to isolate fat-soluble triterpenoids including betulinic acid and inotodiol—is considered the most comprehensive preparation method for preserving the full bioactive spectrum. Betulin has particularly poor aqueous solubility, which limits its absorption from simple water-based teas, and experimental nanosuspension technologies have demonstrated improved bioavailability in preclinical models, though such formulations are not yet widely available commercially.

### Does chaga mushroom interact with medications?

Chaga mushroom's preclinical platelet aggregation-inhibiting activity creates a theoretical pharmacodynamic interaction risk with anticoagulant and antiplatelet drugs such as warfarin, aspirin, clopidogrel, and heparin, potentially increasing bleeding risk. Its demonstrated hypoglycemic activity in rodent models also suggests a possible additive effect with insulin secretagogues, metformin, or other antidiabetic agents, which could result in hypoglycemia; no human pharmacokinetic or drug interaction studies exist to quantify these risks, so patients on these medications should consult a healthcare provider before use.

### What is the difference between chaga mushroom extract and chaga powder, and which form delivers more bioactive compounds?

Chaga extracts use solvents (typically hot water or dual extraction with alcohol) to concentrate polysaccharides and triterpenoids, often achieving 15–30% beta-glucan content, while raw chaga powder contains 3–8% by weight due to the mushroom's dense, woody structure. Dual-extraction or hot-water extracts are generally considered more bioavailable because they break down the fungal cell walls and isolate the immunomodulatory compounds, whereas powder requires digestive breakdown and passes through with lower absorption rates. For maximum efficacy, standardized extracts delivering ≥15% polysaccharides are preferred over non-standardized powders.

### Who should avoid taking chaga mushroom supplements, and are there specific populations where it is contraindicated?

Individuals with autoimmune conditions (lupus, rheumatoid arthritis, multiple sclerosis) should consult a healthcare provider before use, as chaga's immunomodulatory beta-glucans may exacerbate immune dysregulation. People scheduled for surgery within 2 weeks should discontinue chaga due to its anticoagulant properties mediated by ergosterol peroxide and triterpenoids. Pregnant and nursing women lack sufficient safety data and should avoid supplementation until more clinical evidence is available.

### How does the growing substrate (birch vs. other trees) affect the potency and antioxidant content of chaga mushroom?

Chaga grown on birch trees (its native host) contains higher concentrations of bioactive compounds compared to conks from alder or other substrates, with birch-derived chaga demonstrating 287 mg gallic acid equivalents per gram dry weight in antioxidant capacity versus lower levels in alternative substrates. The birch tree's unique biochemistry—including betulin and betulinic acid—transfers into the fruiting body and synergistically enhances chaga's polyphenol profile. Supplement quality and potency can therefore vary significantly based on substrate origin, making birch-sourced chaga generally preferred by practitioners.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*